{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:56Z","timestamp":1792036856572,"version":"4.4.0"},"reference-count":67,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite the recent approval of novel immunotherapies, such as immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal antibodies, Multiple Myeloma (MM) remains incurable, and the acquisition of triple-refractoriness leads to really dismal outcomes in even earlier lines of therapy. More recently, innovative therapeutic strategies targeting B cell maturation antigen (BCMA), highly expressed on the plasma cell surface, are drawing different future landscapes in terms of effectiveness and outcomes. Belantamab Mafodotin, a first-in-class anti-BCMA antibody\u2013drug conjugate, demonstrated good efficacy and safety profile in triple-refractory patients in the phase 2 DREAMM-2 trial, and it was approved for the treatment of MM triple-exposed patients with &gt;4 prior lines of therapy. Here, starting from Belantamab Mafodotin clinical trials and also exploring combination studies and different schedules in order to improve its efficacy and toxicity, we focused on real-life experiences all over the world, which have confirmed clinical trial data and encourage further Belantamab Mafodotin investigations.<\/jats:p>","DOI":"10.3390\/cancers15112948","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T16:17:33Z","timestamp":1685204253000},"page":"2948","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences"],"prefix":"10.3390","volume":"15","author":[{"given":"Sonia","family":"Mor\u00e8","sequence":"first","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero, Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2749-7347","authenticated-orcid":false,"given":"Massimo","family":"Offidani","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero, Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Corvatta","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Complessa di Medicina, Ospedale Profili, 60044 Fabriano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0688-4882","authenticated-orcid":false,"given":"Maria Teresa","family":"Petrucci","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fazio","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Abramson, H.N. (2018). Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. Int. J. Mol. Sci., 19.","DOI":"10.20944\/preprints201810.0577.v1"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bonello, F., Mina, R., Boccadoro, M., and Gay, F. (2020). Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12010015"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101143","DOI":"10.1016\/j.beha.2020.101143","article-title":"Monoclonal Antibodies in Multiple Myeloma: Current and Emerging Targets and Mechanisms of Action","volume":"33","author":"Wudhikarn","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical Course of Patients with Relapsed Multiple Myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric Antigen Receptor T-Cell Therapies for Multiple Myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Soekojo, C.Y., Ooi, M., de Mel, S., and Chng, W.J. (2020). Immunotherapy in Multiple Myeloma. Cells, 9.","DOI":"10.3390\/cells9030601"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-Targeted Immunotherapy for Multiple Myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, Lenalidomide, and Dexamethasone in RRMM: Final Overall Survival Results from the Phase 3 Randomized ELOQUENT-2 Study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in Multiple Myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone in Previously Treated Multiple Myeloma (APOLLO): An Open-Label, Randomised, Phase 3 Trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, Dexamethasone, and Daratumumab versus Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (CANDOR): Results from a Randomised, Multicentre, Open-Label, Phase 3 Study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab before and after Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus Pomalidomide and Low-Dose Dexamethasone versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, Carfilzomib, and Dexamethasone in Relapsed Multiple Myeloma (IKEMA): A Multicentre, Open-Label, Randomised Phase 3 Trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and\/or Refractory Multiple Myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-Week Selinexor, Bortezomib, and Dexamethasone versus Twice-per-Week Bortezomib and Dexamethasone in Patients with Multiple Myeloma (BOSTON): A Randomised, Open-Label, Phase 3 Trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor\u2013Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-12-3752","article-title":"In Vitro and in Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells","volume":"19","author":"Chauhan","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) Is a Potent Cereblon E3 Ligase Modulator with Antitumor and Immunostimulatory Activities in Lenalidomide- and Pomalidomide-Resistant Multiple Myeloma Cells with Dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (BELLINI): A Randomised, Double-Blind, Multicentre, Phase 3 Trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-Label, Phase 2 Study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-Drug Conjugates: Recent Advances in Conjugation and Linker Chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-019-0786-6","article-title":"Antibody-Drug Conjugates in Clinical Trials for Lymphoid Malignancies and Multiple Myeloma","volume":"12","author":"Yu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lu, J., Jiang, F., Lu, A., and Zhang, G. (2016). Linkers Having a Crucial Role in Antibody-Drug Conjugates. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17040561"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.clml.2018.05.006","article-title":"Investigational Antibody-Drug Conjugates for Treatment of B-Lineage Malignancies","volume":"18","author":"Herrera","year":"2018","journal-title":"Clin. Lymphoma. Myeloma Leuk."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-Mediated Antitumor Responses In Vivo","volume":"20","author":"Alavi","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_38","unstructured":"GlaxoSmithKline (2020, August 25). BLENREP (Belantamab Mafotodin-Blmf): EMA Prescribing Information. Available online: Http:\/\/Www.Ema.Europa.Eu\/Medicines\/Human\/Orphan-Designations\/Eu3171925."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer Term Outcomes with Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: 13-Month Follow-up from the Pivotal DREAMM-2 Study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody\u2013Drug Conjugate, GSK2857916, in Relapsed\/Refractory Multiple Myeloma: An Update on Safety and Efficacy from Dose Expansion Phase I Study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_42","first-page":"20","article-title":"Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study","volume":"136","author":"Rathi","year":"2020","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.3324\/haematol.2019.235937","article-title":"Characterization of Response and Corneal Events with Extended Follow-up after Belantamab Mafodotin (GSK2857916) Monotherapy for Patients with Relapsed Multiple Myeloma: A Case Series from the First-Time-in-Human Clinical Trial","volume":"105","author":"Popat","year":"2020","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1111\/bph.14429","article-title":"Identification of Novel Macropinocytosis Inhibitors Using a Rational Screen of Food and Drug Administration-Approved Drugs","volume":"175","author":"Lin","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-139332","article-title":"DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib\/Dexamethasone (BorDex) in Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Popat","year":"2020","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1182\/blood-2022-164877","article-title":"Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial","volume":"140","author":"Nooka","year":"2022","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/1078-0432.CCR-22-0618","article-title":"FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma","volume":"28","author":"Baines","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_48","unstructured":"(2023, February 01). GSK. Available online: Https:\/\/www.Gsk.Com\/En-Gb\/Media\/Press-Releases\/Gsk-Provides-Update-on-Dreamm-3-Phase-iii-Trial-for-Blenrep\/."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1182\/blood-2022-160445","article-title":"Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed\/Refractory Multiple Myeloma","volume":"140","author":"Trudel","year":"2022","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2022-157767","article-title":"No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed\/Refractory Multiple Myeloma","volume":"140","author":"Lowther","year":"2022","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Other BCMA-Targeting Agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/bloodadvances.2021004176","article-title":"Effective Anti-BCMA Retreatment in Multiple Myeloma","volume":"5","author":"Gazeau","year":"2021","journal-title":"Blood Adv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7286","DOI":"10.1182\/blood-2022-162584","article-title":"Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial","volume":"140","author":"Garcia","year":"2022","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1182\/blood-2022-160014","article-title":"A Phase 1\/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma","volume":"140","author":"Terpos","year":"2022","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41408-021-00592-3","article-title":"\u201cReal-Life\u201d Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma\u2014The Mayo Clinic Experience","volume":"11","author":"Vaxman","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.18298","article-title":"Impact of Belantamab Mafodotin-Induced Ocular Toxicity on Outcomes of Patients with Advanced Multiple Myeloma","volume":"199","author":"Abeykoon","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"8060","DOI":"10.1200\/JCO.2022.40.16_suppl.8060","article-title":"Retrospective, Single-Center, Real-World Experience of Belantamab Mafodotin in Relapsed\/Refractory Multiple Myeloma","volume":"40","author":"Becnel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1182\/blood-2022-171077","article-title":"Belantamab Mafodotin in Patients with Relapsed\/Refractory Multiple Myeloma, a Real-World Single Center Experience","volume":"140","author":"Hultcrantz","year":"2022","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"10124","DOI":"10.1182\/blood-2022-164929","article-title":"Belantamab Mafodotin (Belamaf) for Relapsed\/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study","volume":"140","author":"Hultcrantz","year":"2022","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.18479","article-title":"Real-World Experience with Belantamab Mafodotin Therapy for Relapsed\/Refractory Multiple Myeloma: A Multicentre Retrospective Study","volume":"200","author":"Shragai","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.1182\/blood-2022-166399","article-title":"Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study","volume":"140","author":"Offidani","year":"2022","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1026251","DOI":"10.3389\/fonc.2022.1026251","article-title":"Efficacy and Safety of Belantamab-Mafodotin in Triple-Refractory Multiple Myeloma Patients: A Multicentric Real-Life Experience","volume":"12","author":"Iula","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/psp4.12660","article-title":"Population Pharmacokinetics of Belantamab Mafodotin, a BCMA-Targeting Agent in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"10","author":"Rathi","year":"2021","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2022-158538","article-title":"Belantamab Mafodotin in Patients with Relapsed\/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort","volume":"140","author":"Alonso","year":"2022","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2022-156035","article-title":"Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study","volume":"140","author":"Roussel","year":"2022","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Talbot, A., Bobin, A., Tabone, L., Lambert, J., Boccaccio, C., Deal, C., Petillon, M.-O., Allangba, O., Agape, P., and Arnautou, P. (2023). Real-World Study of the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) in Relapsed or Refractory Multiple Myeloma Based on Data from the Nominative ATU in France: IFM 2020-04 Study. Haematologica, Epub ahead of print.","DOI":"10.1016\/S2152-2650(22)00606-1"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/11\/2948\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:43:29Z","timestamp":1760125409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/11\/2948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,27]]},"references-count":67,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["cancers15112948"],"URL":"https:\/\/doi.org\/10.3390\/cancers15112948","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,27]]}}}